89bio Inc (ETNB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 89bio Inc (ETNB) has a cash flow conversion efficiency ratio of -0.192x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-100.42 Million) by net assets ($521.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ETNB cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
89bio Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how 89bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
89bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 89bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bank of N.T. Butterfield & Son Ltd
NYSE:NTB
|
0.052x |
|
Shenzhen Sinexcel Electric Co Ltd
SHE:300693
|
0.116x |
|
Transwarp Technology (Shanghai) Co. Ltd. A
SHG:688031
|
N/A |
|
Fujian Star Net Communic Ltd
SHE:002396
|
0.061x |
|
Hilltop Holdings Inc
NYSE:HTH
|
0.123x |
|
Hunan Aihua Group Co Ltd
SHG:603989
|
0.025x |
|
Torunlar Gayrimenkul Yatirim Ortakligi AS
IS:TRGYO
|
-0.002x |
|
Custom Truck One Source Inc
NYSE:CTOS
|
0.030x |
Annual Cash Flow Conversion Efficiency for 89bio Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of 89bio Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see how much is 89bio Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $400.79 Million | $-367.82 Million | -0.918x | -281.00% |
| 2023-12-31 | $536.31 Million | $-129.19 Million | -0.241x | +54.90% |
| 2022-12-31 | $151.83 Million | $-81.09 Million | -0.534x | +12.39% |
| 2021-12-31 | $125.96 Million | $-76.78 Million | -0.610x | -167.54% |
| 2020-12-31 | $202.96 Million | $-46.24 Million | -0.228x | +19.51% |
| 2019-12-31 | $89.94 Million | $-25.46 Million | -0.283x | -136.45% |
| 2018-12-31 | $-16.06 Million | $-12.47 Million | 0.777x | -- |
About 89bio Inc
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly kn… Read more